Profil
Michal Ayalon worked as Vice President of Research and Development at Kamada Ltd. from 2019 to 2022.
Prior to that, she held the same position at Galmed Pharmaceuticals Ltd. in 2015-2016.
In 2018-2019, she was Head of Research and Development at 89Bio Ltd. Ayalon received her undergraduate, graduate, and doctorate degrees from Tel-Aviv University.
Ehemalige bekannte Positionen von Michal Ayalon
| Unternehmen | Position | Ende |
|---|---|---|
| KAMADA LTD. | Technik-/Wissenschafts-/F&E-Leiter | 28.02.2022 |
89Bio Ltd.
89Bio Ltd. Pharmaceuticals: MajorHealth Technology Develops therapies and drugs for treatments of patients living with nonalcoholic steatohepatitis | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2019 |
| GALMED PHARMACEUTICALS LTD. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2016 |
Ausbildung von Michal Ayalon
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Tel-Aviv University
Tel-Aviv University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kamada Ltd.
Kamada Ltd. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops and manufactures plasma-derived therapeutics products | Health Technology |
Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Develops and manufactures aramchol for non-alcoholic steatohepatitis | Health Technology |
89Bio Ltd.
89Bio Ltd. Pharmaceuticals: MajorHealth Technology Develops therapies and drugs for treatments of patients living with nonalcoholic steatohepatitis | Health Technology |
















